BC Environmental and Occupational Health Research Network

The purpose of this funding opportunity announcement is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity invites studies that address scientific areas potentially relevant to vaccine safety such as:
• physiological and immunological responses to vaccines and vaccine components
• how genetic variations affect immune/physiological responses that may impact vaccine safety
• identification of risk factors and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines, or
• the application of genomic/molecular technologies to improve knowledge of vaccine safety.

The National Institute of Allergy and Infectious Diseases (NIAID), invites applications to participate in a research program that will provide a multidisciplinary approach that integrates clinical and field aspects with laboratory, molecular and genomic methods for malaria control and prevention. The objective of the International Centers of Excellence for Malaria Research (ICEMR) program is to create a group of research centers in malaria-endemic settings that will provide the necessary knowledge, tools, and evidence-based strategies to support intervention and control programs of government organizations and health care institutions. Ultimately, such a broad-based, multidisciplinary and integrated approach is expected to enhance the research underpinnings for effective malaria elimination and possibly eradication. Data and findings generated by these Centers are expected to provide input critical to inform future research design and evaluation of new interventions and control strategies.

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), supports extramural research focused on understanding, controlling and preventing diseases caused by virtually all infectious agents. In response to threats presented by bioterrorism and emerging infectious diseases, the NIAID Division of Microbiology and Infectious Diseases (DMID) has established research programs to facilitate development of countermeasures for select pathogens and toxins.

The purpose of this FOA is to solicit research grant applications to conduct time-sensitive ancillary studies related to heart, lung, and blood diseases and sleep disorders in conjunction with ongoing NIH- or non-NIH-supported clinical trials. The ancillary study can address any research question related to the mission of NHLBI for which the parent study (which can also be an observational study or registry that can provide a sufficient cohort of well-characterized patients) can provide participants, infrastructure, and data. All ancillary study applications must demonstrate the time-sensitive nature of their proposal and must explicitly address why an expedited review is essential to its feasibility.

The National Institute of Allergy and Infectious Diseases (NIAID), invites applications to participate in a research program that will provide a multidisciplinary approach that integrates clinical and field aspects with laboratory, molecular and genomic methods for malaria control and prevention. The objective of the International Centers of Excellence for Malaria Research (ICEMR) program is to create a group of research centers in malaria-endemic settings that will provide the necessary knowledge, tools, and evidence-based strategies to support intervention and control programs of government organizations and health care institutions. Ultimately, such a broad-based, multidisciplinary and integrated approach is expected to enhance the research underpinnings for effective malaria elimination and possibly eradication. Data and findings generated by these Centers are expected to provide input critical to inform future research design and evaluation of new interventions and control strategies.

The purpose of this initiative is to support a broad range of research in basic disciplines including immunology, virology, cellular and structural biology and host genetics that potentially can lead to new discoveries, expanded knowledge, and novel concepts and approaches applicable to the design of an effective prophylactic HIV-1 vaccine. Applications must clearly demonstrate how the proposed research will directly contribute to the design of an effective prophylactic HIV-1 vaccine that prevents infection and/or substantially ameliorates the progression of disease.

The intent of this FOA is to stimulate collaborative research among foreign investigators from the same geographic regions to address regional issues on the intersection of HIV/AIDS and drug use in international settings. NIDA’s objective is to expand research capacity in resource limited areas where HIV associated with injection and /or non-injection drug use is an emerging or prevalent epidemic. This FOA seeks to foster international partnerships among researchers with expertise in epidemiology, the basic biomedical and clinical sciences, behavioral and social sciences, health services, treatment and prevention, or implementation science, with a focus on addressing regional issues. The overall goal of this FOA is to enhance availability of evidence-based biomedical and behavioral strategies which will improve public health approaches to the prevention and treatment of HIV/AIDS associated with drug use. This FOA seeks projects that address prevention and treatment research issues utilizing special collaborative opportunities, expertise, resources, populations or settings to address regionally-focused international issues.

The principal purpose of the research supported through this initiative is to support a broad array of translational studies linking developmental neuroscience and behavioral treatments for drug abusing adolescents (with and without co-morbid psychiatric disorders) across the spectrum of abused drugs. Findings from research on adolescent brain development and the neurobiological, neurocognitive, and neurobehavioral processes that are associated with adolescent development and with substance abuse may provide drug abuse treatment researchers with important data and new approaches for developing and/or adapting treatment interventions for substance use disorders among adolescents. Similarly, a clearer understanding of the specific neurobiological effects and the mechanism of action of treatments may lead to the modification of existing therapies or to the development of more efficacious treatments for drug-addicted individuals that translate into sustainable changes in behavior and improved functioning.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 applications to conduct rigorous, theory-driven research on the effects of recent legislative and regulatory changes, including the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008, affecting insurance coverage for drug abuse treatment services. Research on the effects of health insurance parity legislation and changes in the Medicaid programs needed to enhance understanding of the implementation and consequences of legislative and policy initiatives. Specifically, these natural experiments provide an opportunity to study fundamental scientific questions about how variations in insurance coverage and benefit design affect access to, and the availability, costs, efficiency, quality and outcomes of, drug abuse treatment. Such research may also help inform how benefit packages for these disorders can be optimally designed.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects on evaluating the performance of emerging molecular and cellular analysis technologies utilizing an appropriate cancer-relevant biological system. “Emerging technology” is defined as one that has passed the initial developmental stage and shows promise but has not yet been evaluated within the context of its use or proposed application and has not been commercialized. Therefore, the thrust of effort in the projects proposed in response to this FOA must be on the application of an emerging and potentially transformative technology rather than on its development.

The MIP program is designed to foster the introduction of novel scientific ideas, model systems, tools, agents, targets, and technologies with the potential to iteratively and substantially advance microbicide science. Aims of this research may include identification and development of new, potentially high-risk approaches and antiviral targets for microbicides. Efforts can also include the identification of new lead microbicide candidates or targets through incremental and iterative optimization of the microbicide candidate/target. This may be done by demonstrating: (1) establishment of new pathways to microbicide-related science, (2) in vitro demonstration in a relevant model of efficacy with minimal or no toxicity for newly discovered leads, (3) activity (single dose) or lack of toxicity (multiple dose) in relevant animal models, or (4) preliminary data that establish a strong rationale for the use of the vaginal, rectal and/or penile microbicide or strategy.

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), and the National Institute of Nursing Research (NINR), of the National Institutes of Health, invites applications for basic, pre-clinical, and clinical complementary cancer research. The research should relate to the areas of prevention, diagnosis, and treatment of cancer as well as management of cancer symptoms and side effects due to conventional cancer treatment. In addition, this FOA encourages the development and application of emerging and innovative technologies, including identification of novel therapeutics in the pharmacopoeia of Traditional Medical Systems (as defined by the World Health Organization), use of complementary approaches to improve the therapeutic ratio of standard and investigational anti-cancer therapies, and research on lifestyle modifications (e.g. diet, exercise, mind-body approaches) for their impact on cancer outcomes (e.g., response to conventional cancer therapy, survival). The overarching goals of this FOA is to encourage investigators to submit high quality, preliminary research of humans that will advance the science of Complementary and Alternative Medicine (CAM) and provide a solid foundation and justification for future research project (R01) grant applications to definitively determine the efficacy of CAM approaches.

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), solicits research applications for projects that will advance development of vaccines against five pathogens that have a significant impact on public health: cytomegalovirus, respiratory syncytial virus, Staphylococcus aureus, Pseudomonas aeruginosa and Clostridium difficile. All of these pathogens have been the subject of vigorous vaccine development efforts that to date have not resulted in a successful candidate moving to licensure. Applications that include collaborations between researchers from different disciplines and/or with industry are strongly encouraged, but not required.

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), supports extramural research focused on understanding, controlling and preventing diseases caused by virtually all infectious agents. The NIAID has a long-standing interest in and commitment to global health and international research on infectious diseases. A solid foundation of international research and collaborations enhances the U.S. capacity for infectious disease research and the ability to respond to newly emergent disease threats. Moreover, the availability of NIAID-sponsored overseas study sites for field research advances our global public health agenda and allows for research that might not be possible in the U.S. The International Collaborations in Infectious Disease Research (ICIDR) Program, initiated in 1980, makes awards to U.S. institutions to engage in substantial international collaboration with overseas institutions in tropical medicine and emerging infectious disease research. The goals of the ICIDR program are to: support high-quality, collaborative research that will lead to or result in prevention, amelioration, and/or improved treatment of infectious diseases; increase relevant and collaborative research experience for both U.S. and foreign investigators; and facilitate and enhance scientific linkages between U.S. and foreign investigators to enhance the independent research capacity of the collaborating foreign institutions and foster further international collaborative research projects.

The goal of this initiative is to encourage exploratory/developmental clinical research related to the prevention or treatment of diabetes, obesity and endocrine and genetic metabolic diseases. The Pilot and Feasibility Clinical Research Grants Program is designed to allow initiation of exploratory, short-term clinical studies, so that new ideas may be investigated without stringent requirements for preliminary data. Such support can be used by experienced investigators, as well as new investigators, to pursue new approaches and investigate underdeveloped research areas. The short-term studies should focus on research questions that are likely to have high clinical impact. They can include testing a new prevention strategy, a new intervention, or unique combinations of therapies. A high priority is the use of such studies to help stimulate the translation of promising research developments from the laboratory into clinical practice in diabetes, endocrine diseases and genetic metabolic diseases, including cystic fibrosis.

The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse populations and lead to effective health interventions and services for individuals within and across those groups and populations. High priority is given to research that focuses on understudied, hidden, or difficult-to-access groups that seem to have distinctive health risk profiles but have received relatively little attention by the public health and scientific community. This Funding Opportunity Announcement (FOA) highlights a particular set of such groups: lesbian, gay, bisexual, transgender, intersex, and related populations (designated here as LGBTI populations).

To meet the objectives outlined in the updated NIAID Strategic Plan for Biodefense Research, it is imperative that promising findings/technologies are translated rapidly into new approaches and strategies for product development. The involvement of experts from diverse disciplines (e.g., biochemists, structural biologists, protein chemists, pharmacologists, immunologists, molecular biologists, engineers and clinicians) within academia and industry is needed to enable development of well-designed candidates for vaccines, vaccine technologies. adjuvants, therapeutics, immunotherapeutics, and medical diagnostics. The objective of this RFA is to support research that will advance the development and/or production of countermeasures (vaccines, adjuvants, therapeutics, immunotherapeutics, and medical diagnostics) specific for NIAID Category A, B, or C priority pathogens or toxins. Developmental research is not required to result in a "final" product but must advance the development of a candidate product. A second objective of this RFA is to stimulate scientifically sound, original, and innovative research requiring a comprehensive team and multidisciplinary effort that will facilitate advancement of a promising candidate product or platform technology through the product development pathway.

Tobacco use and HIV/AIDS have an enormous public health impact, and our knowledge of their health effects is informed by a large body of research. However, there is a dearth of understanding of the interactions between these issues at all levels, from basic neuroscience to behavioral and social epidemiology. The purpose of this Program Announcement, therefore, is to stimulate research related to the unique, interactive health effects of tobacco use and HIV/AIDS.

This recognition award is a peer-reviewed recognition award made through the American Health Assistance Foundation. The award is designed to highlight previous achievements in defined research areas.
Maximum duration of the award: 5 years
Topic: Early Detection and Prevention of Alzheimer’s disease.

The initiative is designed to bring together a diverse interdisciplinary group with expertise in genetics/genomics, immunology, microbiology and proteomics along with the more traditional areas of parturition research such as maternal fetal medicine, obstetrics, and pediatrics to address scientific issues related to preterm birth. The Planning Grant may be used for, but not limited to: travel for meetings between members of research groups, sample acquisition for later proposed studies, collection of pilot data, resources to support protocol generation, etc. Also, personnel costs, analysis costs, consumable supplies, animal studies, or human subject recruitment can be supported by the planning grant. BWF does not support indirect costs.